Live Analyst Rating Changes 23586 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Dev Prasad
LUCI

Dev Prasad

Lucid Capital
Wall Street Analyst
★★★★★
#310
on 13Foresight · ranked by our own returns
73%
Success Rate
+65.9%
Average Return
11 of 15 calls profitable · +49.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 73% of Dev Prasad's ratings turned a profit when each position was held for 1 year — averaging +65.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

8 Buy 1 Hold 0 Sell
Dev's Stock Coverage 15 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PLYX
Polaryx Therapeutics, Inc.
 Jul 27, 2026 BUY Strong Buy
+286.3% avg upside
2 analysts
$7.00
218.10% Upside
 +15.3% ·
QNRX
Quoin Pharmaceuticals
 May 04, 2026 BUY Strong Buy
+473.6% avg upside
7 analysts
$30.00
460.73% Upside
 -24.7% ·
ABOS
Acumen Pharmaceuticals
 Dec 17, 2025 BUY Strong Buy
+229.4% avg upside
10 analysts
$6.00
142.82% Upside
 +20.5% ·
PVLA
Palvella Therapeutics
 Dec 15, 2025 BUY Strong Buy
+9.4% avg upside
27 analysts
$212.00
37.39% Upside
 +73.4% ·
IFRX
InflaRx
 Nov 10, 2025 BUY Buy
+348.8% avg upside
11 analysts
$24.00
1099.94% Upside
 +16.5% ·
VRCA
Verrica Pharmaceuticals
 Nov 05, 2025 BUY Strong Buy
+250.2% avg upside
8 analysts
$19.00
263.95% Upside
 +48.4% ·
TSE:MDNA
Medicenna Therapeutics Corp
 Oct 14, 2025 BUY Strong Buy
+1121.7% avg upside
9 analysts
$4.00
899.98% Upside
 -59.2% ·
ATYR
aTyr Pharma
 Sep 15, 2025 HOLD Buy
+1473.5% avg upside
17 analysts
$1.00
87.21% Upside
 -50.5% ·
CUE
Cue Biopharma
 Aug 25, 2025 BUY Strong Buy
-64.2% avg upside
9 analysts
$4.00
85.84% Downside
 +8.6% ·
IRD
Opus Genetics
 Jun 17, 2025 BUY Strong Buy
+175.0% avg upside
25 analysts
$5.00
28.96% Upside
 +341.3% ·
EDSA
Edesa Biotech
 May 23, 2025 BUY Strong Buy
+106.0% avg upside
6 analysts
$9.00
63.01% Upside
 +433.7% ·
ALGS
Aligos Therapeutics
 May 01, 2025 BUY Strong Buy
+526.2% avg upside
11 analysts
$36.00
394.42% Upside
 +0.9% ·
IBIO
Ibio
 Dec 17, 2024 BUY Strong Buy
+305.4% avg upside
11 analysts
$6.00
308.20% Upside
 -21.9% ·
CALC
CalciMedica
 Dec 17, 2024 BUY Buy
+4235.8% avg upside
9 analysts
$13.00
1876.61% Upside
 +80.6% ·
AVTX
Avalo Therapeutics
 Dec 17, 2024 BUY Strong Buy
+167.3% avg upside
20 analysts
$24.00
23.26% Upside
 +105.2% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Dev Prasad — Frequently Asked Questions
How accurate are Dev Prasad's stock ratings?
Based on the calls 13Foresight could measure, about 73% of Dev's ratings were profitable over a one-year hold, with an average return of +65.9% per rating, or +49.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Dev ranked on 13Foresight?
Dev Prasad is currently ranked #310 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Dev cover?
Dev most recently has ratings on PLYX, QNRX, ABOS, PVLA, IFRX, VRCA, TSE:MDNA, ATYR, CUE, IRD, EDSA, ALGS and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.